Teva Makes The Cut: 5,000 Jobs To Be Eliminated
This article was originally published in The Pink Sheet Daily
Executive Summary
The generic drug manufacturer said it will accelerate its cost reduction program and shrink its global workforce by 5,000 employees amid slowing sales growth and the looming threat of competition to its blockbuster branded medicine, Copaxone.